Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioma: early-phase trial registry
48 of 88 indexed Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #156 of 28,707 conditions by registered trial count.
88 US clinical trials · 48 currently recruiting · #156 of 28,707 conditions by registered trial count
Glioma: 88 US clinical trials tracked, 48 recruiting.
Glioma is the subject of 88 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 53 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition glioma
OPEN 48 | RECR 55% | LATE 3 | EARLY 53 | RANK #156 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Glioma lists 48 open slots (55% of 88 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioma is recruiting above its size-band peers.
48 of 88 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 8 of 88 trials (9.1%). 51 distinct sponsors appear on at least one study for this condition label.
-
Most Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 88 trials that report a genuine target (sentinel values excluded). 67 of those (76.1%) plan for fewer than 100 participants.
-
Glioma research is mostly interventional.
78 interventional and 10 observational studies make up this index (88.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
88 total, page 2 of 2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT04521686
Multimodal Machine Learning Characterization of Solid Tumors
Ciprian Catana, MD, PhD
NCT04687969
Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients
M.D. Anderson Cancer Center
NCT05511324
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
NCT03180502
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Nader Sanai
NCT05182905
Assessing Brain Metabolism Using MRS With Deuterated Glucose
University of California, San Francisco
NCT06594315
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT03718767
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
NCT03514069
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
M.D. Anderson Cancer Center
NCT04186832
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
NCT06413706
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
University of California, San Francisco
NCT03739372
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
NCT03687957
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
Jonsson Comprehensive Cancer Center
NCT05045027
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Memorial Sloan Kettering Cancer Center
NCT02658279
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Boehringer Ingelheim
NCT05916313
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Seattle Children's Hospital
NCT03500991
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Cancer Institute (NCI)
NCT05413304
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Institut de Recherches Internationales Servier
NCT02481154
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
NCT01682187
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals
NCT01465347
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Wake Forest University Health Sciences
NCT02747407
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT00108069
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
NCT02781792
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
Abramson Cancer Center at Penn Medicine
NCT01020292
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
National Cancer Institute (NCI)
NCT00001573
Resting-State Functional MRI in Glioma Patients Before and After Surgery
M.D. Anderson Cancer Center
NCT03964909
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Jennie Taylor
NCT02549833
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
University of Michigan Rogel Cancer Center
NCT02805179
A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
Hoffmann-La Roche
NCT00532948
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
NCT03551249
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
Blaze Bioscience
NCT02234297
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Jason J. Luke, MD
NCT04056910
GW572016 to Treat Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
NCT00107003
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03027388
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
Washington University School of Medicine
NCT01999270
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
Annick Desjardins
NCT00979173
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 38 |
| Phase 2 | 15 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioma page
88 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioma condition card totals 88 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.